Population pharmacokinetic analysis of the active product of dipyrone

International Journal of Clinical Pharmacology and Therapeutics

Volumn 48, Issue 12, 2010, Pages 791-797

  Levy, M ^a   Muszkat, M ^a   Rich, B ^b   Rosenkranz, B ^c   Schlattmann, P ^d  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^b MCGILL UNIVERSITY   (Canada)

^c STELLENBOSCH UNIVERSITY   (South Africa)

^d JENA UNIVERSITY HOSPITAL   (Germany)

Author keywords

Clearance; Dipyrone; MAA; Nonlinear mixed effects models; Population pharmacokinetics

Indexed keywords

4 METHYL AMINO ANTIPYRINE; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CREATININE; DIPYRONE; DRUG METABOLITE; UNCLASSIFIED DRUG;

ACCURACY; ADOLESCENT; ADULT; AGE; AGED; ARTICLE; BAYES THEOREM; CONTROLLED STUDY; DEMOGRAPHY; DRUG CLEARANCE; DRUG DETERMINATION; DRUG DISPOSITION; DRUG EFFECT; ETHNICITY; FEMALE; FEVER; HUMAN; INTERMETHOD COMPARISON; ISRAEL; KIDNEY FUNCTION; LIVER FUNCTION; MAJOR CLINICAL STUDY; MALE; PAIN; POPULATION DISTRIBUTION; PREDICTION; PROCESS DEVELOPMENT; STATISTICAL MODEL;

EID: 78650848624     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CPP48791     Document Type: Article

References (13)

1. Beal S, Sheiner L. Estimating population kinetics. Crit Rev Biomed Eng. 1982; 8: 195-222. (Pubitemid 13509371)
2. Flusser D, Zylber-Katz E, Granit L, Levy M. Influence of food on the pharmacokinetics of dipyrone. Eur J Clin Pharmacol. 1988; 34: 105-107.
3. Levy M, Blum A, Caraco Y, Granit L, Zylber-Katz E. The kinetics of the dipyrone product 4-methyl-aminoantipyrine in patients with with liver cirrhosis. Drug Investigation. 1992; 4: 219-226.
4. Levy M, Zylber-Katz E, Rosenkranz B. Clinical pharmacokinetics of dipyrone and its metabolites. Clin Pharmacokin. 1995; 28: 216-234.
5. Lindstrom M, Bates D. Nonlinear mixed effects models for repeated measures data. Biometrics. 1990; 46: 673-687.
6. Lunn D, Best N, Thomas A, Wakefield J, Spiegelhalter D. Bayesian analysis of population PK/PD models: general concepts and software. J Pharmacokinet Pharmacodyn. 2002; 29: 271-307.
7. Meineke I, Turck D. Population pharmacokinetic analysis of meloxicam in rheumatoid arthritis patients. British Journal of Clinical Pharmacology. 2003; 55: 32-38.
8. R Development Core Team. R: Alanguage and environment for statistical computing.Vienna,Austria:R Foundation for Statistical Computing; 2006.
9. Roe DJ, Vonesh EF, Wolfinger RD, Mesnil F, Mallet A. Comparison of population pharmacokinetic modeling methods using simulated data: Results from the population modeling workgroup. Statistics in Medicine. 1997; 16: 1241-1262.
10. Rosenkranz B, Lange C, Schmidt D. Pharmacokinetics of Dipyrone in renal insufficiency. In: Abstracts XIIth International Congress of Nephrology. Jerusalem. 1993.
11. Sun H, Fadiran E, Jones C, Lesko L, Huang S, Higgins K, Hu C, Machado S, Maldonado S,Williams R, Hossain M, Ette E. Population pharmacokinetics. A regulatory perspective. Clin Pharmacokinet. 1999; 37: 41-58.
12. Zylber-Katz E, Granit L, Drayer D, Levy M. Simultaneous determination of dipyrone metabolites in plasma by high-performance liquid chromatography. J Chromatogr. 1984; 305: 477-484.
13. Zylber-Katz E, Granit L, Stessman J, Levy M. Effect of age on the pharmacokinetics of dipyrone. Eur J Clin Pharmacol. 1989; 36: 513-516.